HIF1A and non-small cell lung carcinoma: To validate the IPA results, we treated NSCLC cells with WFA or a combination of WFA and STATTIC (STAT-3 inhibitor), PX-478 (HIF1α inhibitor), or brusatol (NRF-2 inhibitor).